

8 - 757

mycoses

Diagnosis, Therapy and Prophylaxis of Fungal Diseases

Edited by/Herausgegeben von:

J. Müller (Editor-in-Chief), Freiburg
Yvonne M. Clayton, London
H. Seeliger, Würzburg

Editorial Board/ Herausgeberkollegium:

L. Ajello, Atlanta
D. M. Dixon, Bethesda
H. C. Korting, München
H. Merk, Köln
Annemarie Polak-Wyss, Basel
P. Régli, Marseille
R. Rüchel, Göttingen

Volume 37 (1994)

8 Med. 68 737

REGISTER

37
1994

Contents
Subject Index
Index of Authors

+ Suppl.

Blackwell Wissenschafts-Verlag GmbH · Kurfürstendamm 57 · D-10707 Berlin

ISSN 0933-7407

Universitäts-
Bibliothek
Lund

CONTENTS

Issue 1/2

- 1-2 **Editorial**
Homage to Wolf Meinof
- 3-10 **E. Guého, L. Improvisi, G. S. De Hoog, B. Dupont.**
Review article. *Trichosporon* on humans: a practical account
Trichosporon am Menschen: Eine Darstellung für die Praxis
- 11-16 **J. Brasch, M. Zaldua.**
Enzyme patterns of dermatophytes
Enzymmuster von Dermatophyten
- 17-21 **J. W. Hülsewede, H. Dermoumi.**
Comparison of high-performance liquid chromatography and bioassay of amphotericin B in serum
Vergleich von Hochleistungs-Flüssigchromatographie und Bioassay für die Bestimmung von Amphotericin B in Serum
- 23-26 **J. Chander, R. K. Sapra, P. Talwar.**
Incidence of cryptococcosis in and around Chandigarh, India, during the period 1982-91
Cryptococcose-Häufigkeit in und um Chandigarh, Indien, im Zeitraum 1982-91
- 27-33 **Y. Mikami, T. Sakamoto, K. Yazawa, T. Gono, Y. Ueno, S. Hasegawa.**
Comparison of *in vitro* antifungal activity of itraconazole and hydroxy-itraconazole by colorimetric MTT assay
Vergleich der antimykotischen Aktivität von Itraconazol und Hydroxy-Itraconazol *in vitro* im kolorimetrischen MTT-Test
- 35-38 **E. Thoma-Greber, H. C. Korting, J. Bogner, F.-D. Goebel.**
Fluconazole-resistant oral candidosis in a repeatedly treated female AIDS patient
Fluconazol-resistente orale Candidose bei einer wiederholt behandelten AIDS-Patientin
- 39-41 **H. C. Gugnani, L. E. Akpata, M. K. Gugnani, R. Srivastava.**
Isoconazole nitrate in the treatment of tropical dermatomycoses
Isoconazolnitrat-Behandlung tropischer Dermatomykosen
- 43-48 **A. R. Khosravi, M. R. Aghamirian, M. Mahmoudi.**
Dermatophytoses in Iran
Dermatophytosen in Iran
- 49-52 **P. Manzano-Gayosso, L. J. Méndez-Tovar, F. Hernández-Hernández, R. López-Martínez.**
Dermatophytoses in Mexico City
Dermatophytosen in Mexico City
- 53-57 **M. A. Ismail, M. A. Abdel-Sater.**
Mycoflora inhabiting water closet environments
Die Mykoflora im WC-Bereich
- 59-60 **E. S. Kuttin, J. Müller.** The fungal flora of zoo animals' ears
Die Pilzflora in den Ohren von Zoo-Tieren
- 61-63 **R. D. Khulbe, G. S. Bisht, C. Joshi.**
Epizootic infection due to *Achlya debaryana* in a catfish
Epizootische Infektion durch *Achlya debaryana* in einem Katzenfisch

Issue 3/4

- 69 **Letter to the Editor**
 71–78 **G. S. de Hoog, F. D. Marvin-Sikkema, G. A. Lahpoor, J. C. Gottschall, R. A. Prins, E. Guého.**
 Ecology and physiology of the emerging opportunistic fungi *Pseudallescheria boydii* and *Scedosporium prolificans*
 Ökologie und Physiologie der opportunistischen Pilze *Pseudallescheria boydii* und *Scedosporium prolificans*
- 79–84 **M. Bock, M. Maiwald, R. Kappe, P. Nickel, H. Näher.**
 Polymerase chain reaction-based detection of dermatophyte DNA with a fungus-specific primer system
 Nachweis von Dermatophyten-DNA durch Polymerase-Ketten-Reaktion mit einem pilzspezifischen Primersystem
- 85–92 **I. Lambkin, A. J. Hamilton, R. J. Hay.**
 Partial purification and characterization of a 235 000 M_r extracellular proteinase from *Trichophyton rubrum*
 Partielle Reinigung und Charakterisierung einer 235 000 M_r extrazellulären Proteinase von *Trichophyton rubrum*
- 93–99 **M. Hamood, P. F. Bluche, C. De Vroey, F. Corazza, W. Bujan, P. Fondu.**
 Effects of recombinant human granulocyte-colony stimulating factor on neutropenic mice infected with *Candida albicans*: acceleration of recovery from neutropenia and potentiation of anti-*C. albicans* resistance
 Die Wirkung von menschlichem Granulozytenkolonien stimulierendem Faktor auf neutropenische, *C. albicans*-infizierte Mäuse: Beschleunigte Normalisierung der Granulozytenzahl und Verstärkung der Resistenz gegenüber *C. albicans*
- 101–107 **H. E. Jensen, B. Aalbaek.**
 Pathogenicity of yeasts and algae isolated from bovine mastitis secretions in a murine model
 Die Pathogenität von Hefe- und Algen-Isolation aus Rindermastitis-Sekreten bei experimenteller Infektion von Mäusen
- 109–226 **A. Dörlemann, H. Listemann, F. Iglauer.**
 Invasive *Trichosporon beigelii* infection in immunosuppressed rats
 Invasive *Trichosporon beigelii*-Infektion bei immunsupprimierten Ratten
- 117–122 **J. E. Arrese, P. Delvenne, J. Van Cutsem, C. Piérard-Franchimont, G. E. Piérard.**
 Experimental aspergillosis in guinea pigs: influence of itraconazole on fungaemia and invasive fungal growth
 Experimentelle Aspergillose bei Meerschweinchen. Der Einfluß von Itraconazol auf Fungämie und invasives Pilzwachstum
- 123–126 **M.-L. Kerkmann, R. Blaschke-Hellmessen, H.-D. Mikulin.**
 Case Report. Successful treatment of cerebral aspergillosis by stereotactic operation and antifungal therapy
 Erfolgreiche Behandlung einer zerebralen Aspergillose durch stereotaktische Operation und antimykotische Therapie
- 127–130 **A. Wildfeuer, J. Faergemann, H. Laufen, G. Pfaff, T. Zimmermann, H. P. Seidl, P. Lach.**
 Bioavailability of fluconazole in the skin after oral medication
 Bioverfügbarkeit von Fluconazol in der Haut nach oraler Medikation
- 131–135 **E. Budtz-Jørgensen, P. Carlino.**
 A miconazole lacquer in the treatment of *Candida*-associated denture stomatitis
 Ein Miconazol-Lack zur Behandlung *Candida*-assoziierter Prothesenstomatitis
- 137–139 **L. Borradori, M. Harms.**
 Case Report. Podopompholyx due to pemphigus vulgaris and *Trichophyton rubrum* infection. Report of an unusual case
 Podopompholyx durch Pemphigus vulgaris und *Trichophyton rubrum*. Bericht über einen ungewöhnlichen Fall

- 141–142 **P. Thomas, H. C. Korting, W. Strassl, T. Ruzicka.**
Case Report. *Microsporum canis* infection in a 5-year-old boy: transmission from the interior of a second-hand car
Microsporum canis-Infektion eines fünfjährigen Jungen: Übertragung durch die Inneneinrichtung eines Gebrauchtwagens
- 143 **Obituary.**
Hans-Heinrich Rieth 1914–1994

Issue 5/6

- 149–153 **R. O. Abuodeh, G. M. Scalarone.**
Comparative studies on the detection of delayed dermal hypersensitivity in experimental animals with lysate and filtrate antigens of *Blastomyces dermatitidis*
Vergleichende Untersuchungen zur Haut-Überempfindlichkeitsreaktion vom verzögerten Typ an Versuchstieren mit Lysat- und Filtratantigenen von *Blastomyces dermatitidis*
- 155–160 **M. L. Orr, J. L. Bono, R. O. Abuodeh, S. J. Williams, A. M. Legendre, G. M. Scalarone.**
Comparative stability, sensitivity and specificity studies with different lots of *Blastomyces dermatitidis* yeast and mycelial lysate antigens
Vergleichende Untersuchungen zur Stabilität, Sensitivität und Spezifität unterschiedlicher Herstellungschargen von *Blastomyces dermatitidis*-Lysatantigenen der Hefe- und Myzelphase
- 161–163 **J. O. Lopes, S. H. Alves, J. P. Benevenga, A. C. Rosa.**
Case Report. The second case of peritonitis due to *Histoplasma capsulatum* during continuous ambulatory peritoneal dialysis in Brazil
Die zweite *Histoplasma capsulatum*-Peritonitis bei kontinuierlicher ambulatorischer Peritonealdialyse in Brasilien
- 165–169 **A. M. da Silva, C. M. Borba, P. C. de Oliveira.**
Viability and morphological alterations of *Paracoccidioides brasiliensis* strains preserved under mineral oil for long periods of time
Überlebensfähigkeit und morphologische Veränderungen von *Paracoccidioides brasiliensis*-Stämmen bei Langzeit-Mineralölkonservierung
- 171–179 **B. Lebeau, H. Pelloux, C. Pinel, M. Michallet, J. P. Goût, C. Pison, P. Delormas, J. P. Bru, J. P. Brion, P. Ambroise-Thomas, R. Grillot.**
Itraconazole in the treatment of aspergillosis: a study of 16 cases
Itraconazol in der Behandlung der Aspergillose: Eine Studie von 16 Fällen
- 181–185 **B. Neumeister, W. Hartmann, M. Oethinger, B. Heymer, R. Marre.**
Case Report. A fatal infection with *Alternaria alternata* and *Aspergillus terreus* in a child with agranulocytosis of unknown origin
Letale Infektion mit *Alternaria alternata* und *Aspergillus terreus* bei einem Kind mit Agranulozytose unbekannter Genese
- 187–190 **G. D. Taylor, M. Buchanan-Chell, T. Kirkland, M. McKenzie, R. Wiens.**
Trends and sources of nosocomial fungaemia
Trends und Ursprünge nosokomialer Fungämien
- 191–197 **V. L. Bykov, E. N. Pakhomova.**
Histopathology of experimental vaginal candidosis in immunosuppressed mice
Die Histopathologie der experimentellen Vaginalcandidose bei immunsupprimierten Mäusen
- 199–204 **L. Klingspor, T. H. Eberhard, G. Stintzing, J. Tollemar.**
Antibody response to *Candida* and its use in clinical practice
Die Antikörperbildung gegen *Candida* und deren Anwendung in der klinischen Praxis
- 205–207 **M. Scheven, L. Senf.**
Quantitative determination of fluconazole-amphotericin B antagonism to *Candida albicans* by agar diffusion
Quantitative Bestimmung des Fluconazol-Amphotericin B-Antagonismus an *Candida albicans* mittels Agardiffusion

- 209–215 **R. Manfredi, A. Mazzoni, O. Cavicchi, D. Santini, F. Chiodo.**
Case Reports. Invasive mycotic and actinomycotic oropharyngeal and craniofacial infection in two patients with AIDS
Invasive Pilz- und Strahlenpilzinfektion in Mund-Rachen-Kraniofazialbereich bei zwei AIDS-Patienten
- 217–219 **I.-G. Bergbrant, J. Faergemann.**
Adherence of *Malassezia furfur* to human stratum corneum cells *in vitro*: a study of healthy individuals and patients with seborrhoeic dermatitis
Adhärenz von *Malassezia furfur* an Stratum corneum-Zellen *in vitro*: Eine Studie an gesunden Personen und Patienten mit seborrhoischem Ekzem
- 221 **Obituary.**
Raymond Vanbreuseghem

Issue 7/8

- 229–233 **M. Knoke, G. Schwesinger.**
One hundred years ago: the history of cryptococcosis in Greifswald. Medical mycology in the nineteenth century
Vor 100 Jahren: Die Geschichte der Cryptococcose in Greifswald. Medizinische Mykologie im 19. Jahrhundert
- 235–242 **J. M. J. Uijthof, C. S. de Hoog, A. W. A. M. de Cock, K. Takeo, K. Nishimura.**
Pathogenicity of strains of the black yeast *Exophiala (Wangiella) dermatitidis*: an evaluation based on polymerase chain reaction
Bewertung der Pathogenität von Stämmen der schwarzen Hefe *Exophiala (Wangiella) dermatitidis* mittels Polymerase-Kettenreaktion
- 243–248 **J. van Cutsem.**
Prophylaxis of *Candida* and *Aspergillus* infections with oral administration of itraconazole
Prophylaxe von *Candida*- und *Aspergillus*-Infektionen durch orale Verabreichung von Itraconazol
- 249–253 **M. Thérizol-Ferly, M. Kombila, M. Gomez de Diaz, T. H. Duong, D. Richard-Lenoble.**
White piedra and *Trichosporon* species in equatorial Africa. I. History and clinical aspects: an analysis of 449 superficial inguinal specimens
Weiße Piedra und *Trichosporon*-Arten in Äquatorialafrika. I. Klinische Aspekte: Eine Analyse von 449 oberflächlichen Untersuchungsproben der Inguinalregion
- 255–260 **M. Thérizol-Ferly, M. Kombila, M. Gomez de Diaz, C. Douchet, Y. Salaun, A. Barrabes, T. H. Duong, D. Richard-Lenoble.**
White piedra and *Trichosporon* species in equatorial Africa. II. Clinical and mycological associations: an analysis of 449 superficial inguinal specimens
Weiße Piedra und *Trichosporon*-Arten in Äquatorialafrika. II. Klinische und mykologische Aspekte. Eine Analyse von 449 oberflächlichen Untersuchungsproben der Inguinalregion
- 261–264 **C. Douchet, M. Thérizol-Ferly, M. Kombila, T. H. Duong, M. Gomez de Diaz, A. Barrabes, D. Richard-Lenoble.**
White piedra and *Trichosporon* species in equatorial Africa. III. Identification of *Trichosporon* species by slide agglutination test
Weiße Piedra und *Trichosporon*-Arten in Äquatorialafrika. III. Identifizierung von *Trichosporon*-Arten mittels Objektträger-Agglutinationstest
- 265–269 **J. I. Okafor.** Purification and characterization of protease enzymes of *Basidiobolus* and *Conidiobolus* species
Reinigung und Charakterisierung von Proteasen von *Basidiobolus*- und *Conidiobolus*-Arten

- 271-274 **J. Naidu, S. M. Singh.**
Aspergillus chevalieri (Mangin) Thom and Church: a new opportunistic pathogen of human cutaneous aspergillosis
Aspergillus chevalieri (Mangin) Thom und Church: Ein neuer opportunistischer Erreger von kutaner Aspergillose beim Menschen
- 275-279 **T. Reblin, A. Meyer, H. Albrecht, H. Greten.**
 Disseminated cryptococcosis in a patient with AIDS
 Disseminierte Cryptococcose bei einem AIDS-Patienten
- 281-283 **M. Yoshida, M. Hiruma, T. Tezuka.**
 A case of sporotrichosis treated successfully with oral fluconazole 200 mg once weekly
 Ein erfolgreich mit 200 mg Fluconazol einmal wöchentlich behandelter Sporotrichose-Fall
- 285-289 **A. Arias, M. P. Arévalo, A. Andreu, C. Rodríguez, A. Sierra.**
In vitro susceptibility of 545 isolates of *Candida* spp. to four antifungal agents
 Empfindlichkeit in vitro von 545 *Candida*-Isolaten für vier Antimyzetika
- 291-294 **F. Walther, U. Kaben, M. Radke, R. Terpe, H. J. Stolpe.**
 Candidosis of the urinary tract with padding phenomenon of the renal pelvises in an infant with obstructive uropathy
 Candida-Mykose des Harntraktes mit Ausgußphänomen der Nierenbecken bei einem Säugling mit obstruktiver Uropathie
- 295-298 **M. K. Rai, S. Qureshi.**
 Screening of different keratin baits for isolation of keratinophilic fungi
 Keratin als Köder zur Isolierung keratinophiler Pilze aus Erdböden
- 299-301 **S. K. Jain, S. C. Agrawal.**
 Fungitoxic effect of some organic volatile substances against fungi causing otomycosis
 Die fungitoxische Wirkung einiger flüchtiger Stoffe auf Otomykose-Erreger

Issue 9/10

- 307-312 **J. M. J. Uijthof, A. W. A. De Cock, G. S. De Hoog, W. G. V. Quint, A. Van Belkum**
 Polymerase chain reaction-mediated genotyping of *Hortaea werneckii*, causative agent of tinea nigra
 PCR-Genotypisierung des Erregers der Tinea nigra, *Hortaea werneckii*
- 313-316 **A. S. Sekhon, L. Kaufman, G. S. Kobayashi, N. Moledina, M. Jalbert, R. H. Notenboom**
 Comparative evaluation of the PremierTM enzyme immunoassay, micro-immunodiffusion and complement fixation tests for the detection of *Histoplasma capsulatum* var. *capsulatum* antibodies
 Vergleichende Bewertung des Premier^R Enzymimmunassays, der Mikroimmundiffusion und der Komplementbindungsreaktion zum Nachweis von Antikörpern gegen *Histoplasma capsulatum* var. *capsulatum*
- 317-323 **C. De Moraes Borba, M. N. S. L. Meirelles, A. M. Mendes Da Silva, P. C. De Oliveira**
Paracoccidioides brasiliensis protoplast production by enzymatic treatment
 Protoplastenbildung bei *Paracoccidioides brasiliensis* durch enzymatische Behandlung
- 325-327 **L. R. Castanón-Olivares, R. López-Martínez**
 Isolation of *Cryptococcus neoformans* from pigeon (*Columba livia*) droppings in Mexico City
 Isolierung von *Cryptococcus neoformans* aus Taubenexkrementen (*Columba livia*) in Mexiko-Stadt
- 329-335 **M. Von Eiff, N. Roos, W. Fegeler, C. Von Eiff, M. Zühlsdorf, J. Glaser, J. Van De Loo.**
 Pulmonary fungal infections in immunocompromised patients: incidence and risk factors
 Pilzbedingte Lungeninfektionen bei abwehrgeschwächten Patienten: Häufigkeit und Risikofaktoren
- 337-341 **H. Mittag.**
 Structural alterations in *Candida albicans* by caffeine and caffeine salts
 Durch Coffein und Coffeinsalze bedingte Strukturänderungen an *Candida albicans*

- 343–347 **R. Grillot, V. Portmann-Coffin, P. Ambroise-Thomas.**
Growth inhibition of pathogenic yeasts by *Pseudomonas aeruginosa* in vitro: clinical implications in blood cultures
Zur Wachstumshehmung pathogener Hefen durch *Pseudomonas aeruginosa* in vitro: Ihre klinische Bedeutung in Blutkulturen
- 349–352 **H. Kaminishi, A. Iwata, T. Tamaki, T. Cho, Y. Hagihara.**
Spiral hyphae of *Candida albicans* formed in anaerobic culture
Spiralhyphen bei *Candida albicans* unter anaeroben Kulturbedingungen
- 353–255 **C. A. Oyeka.**
Isolation of *Candida* species from bats in Nigeria
Die Isolierung von *Candida*-Arten bei Fledermäusen in Nigeria
- 357–360 **J. Perera, Y. Clayton.**
Incidence, species distribution and antifungal sensitivity pattern of vaginal yeasts in Sri Lankan women
Häufigkeit, Artenspektrum und Antimykotika-Empfindlichkeit von Vaginalhefen bei Frauen in Sri Lanka
- 361–365 **E. G. Jung, P. J. Haas, M. Bräutigam, G. Weidinger.**
Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole
Systemische Behandlung von Haut-Candidosen: Ein randomisierter Vergleich von Terbinafin und Ketoconazol
- 367–370 **S. Ross, M. D. Richardson, J. R. Graybill.**
Association between *Malassezia furfur* colonization and seborrhoeic dermatitis in AIDS patients
Zur Assoziation von *Malassezia furfur*-Besiedlung und seborrhoischer Dermatitis bei AIDS-Patienten
- 371–376 **U. Siesenop, K. H. Böhm, E. Brandebusemeyer, P. Conrad.**
Studies on growth, spore-forming ability and virulence of the vaccine strain TV-M-310 of the vaccine Bioveta against ringworm
Untersuchungen zur Wachstumsintensität, Sporenbildungsfähigkeit und Virulenz des Impfstammes TV-M-310 der Trichophytie-Vakzine Bioveta
- 377–383 **D. Mares, C. Romagnoli, R. Rossi, A. Carpita, M. Ciofalo, A. Bruni**
Antifungal activity of some 2,2':5',2"-tertiophene derivatives
Die fungitoxische Wirkung von 2,2':5',2"-Tertiophen-Derivaten

Issue 11/12

- 389–392 **R. Aho, Y. Horie, K. Nishimura, M. Miyaji.**
Aspergillus arvii spec. nov., a new animal pathogen?
Aspergillus arvii spec. nov., eine neue tierpathogene Art?
- 393–399 **H. Mittag.**
Fine structural investigation of *Malassezia furfur*: I. Size and shape of the yeast cells and a consideration of their ploidy
Fein-strukturelle Untersuchung von *Malassezia furfur*: I. Größe und Form der Hefezellen mit Überlegungen zu ihrem Ploidiegrad
- 401–403 **B. Willinger, A. Berger, Lin Li, A. M. Hirschl, Ch. Aspöck, A. Makristhathis, P. M. Prückl, M. L. Rotter.**
Epidemiological analysis of *Candida* yeasts by pulsed-field gel electrophoresis
Wechselfeld-Gelelektrophorese zur epidemiologischen Analyse von *Candida*-Isolaten
- 405–410 **I. Berdicevsky, N. Mirsky.**
Effects of insulin and glucose tolerance factor (GTF) on growth of *Saccharomyces cerevisiae*
Der Einfluß von Insulin und Glucosetoleranzfaktor (GTF) auf das Wachstum von *Saccharomyces cerevisiae*

- 411–416 **M. Del Poeta, F. Barchiesi, D. Arzeni, G. Marinucci, G. Scalise.**
Turbidimetric and visual criteria for *in vitro* susceptibility testing of *Cryptococcus neoformans* clinical isolates
Turbidimetrische und visuelle Kriterien für einen *In vitro*-Empfindlichkeitstest für klinische Isolate von *Cryptococcus neoformans*
- 417–420 **P. Schramm, A. Wildfeuer, E. Sarnow.**
Determination of fluconazole concentrations in the prostatic and seminal vesicle fluid (split ejaculate)
Fluconazol-Konzentrationsbestimmung in Prostata- und Vesikeldrüsensekret (Split Ejakulat)
- 421–425 **D. Sima, H.-J. Tietz, H. Reißhauer, I. Buchholtz, P. Schulze, R. Meyer.**
Case Report. Invasive metastasing pulmonary aspergillosis under polychemotherapy
Invasive metastasierende Lungen-Aspergillose unter Polychemotherapie
- 427–431 **G. P. Prokopowicz, S. F. Bradley, C. A. Kauffman.**
Case Report. Indolent zygomycosis associated with deferoxamine chelation therapy
Schmerzfreie Zygomykose bei Deferoxamin-Chelattherapie
- 433–437 **M. Nucci, W. Pulcheri, P. C. Bacha, N. Spector, M. J. Caiuby, R. O. Costa, H. P. de Oliveira.**
Amphotericin B followed by itraconazole in the treatment of disseminated fungal infections in neutropenic patients
Itraconazol nach Amphotericin B in der Behandlung disseminierter Pilzinfektionen bei neutropenischen Patienten
- 439–441 **J. Nowicka, G. Mazur, K. Kuliczowski, A. Gola, A. Kochman, E. Baran, B. Walów.**
Case Report. Cryptococcal infection and lymphogranulomatous infiltration of the central nervous system in Hodgkin's disease
Cryptococcose und lymphogranulomatöse Infiltration des Zentralnervensystems bei Morbus Hodgkin
- 443–446 **M. J. Torres-Valdivieso, J. López, C. Melero, J. L. Vivanco, E. Cela, A. Garcia, J. Ruíz Contreras, C. Serrano.**
Case Report. Hepatosplenic candidosis in an immunosuppressed patient responding to fluconazole
Hepatosplenale Candidose bei einem immundefizitären Patienten mit erfolgreicher Fluconazoltherapie
- 447–449 **A. Wildfeuer, H. P. Seidl.**
The *in vitro* activity of fluconazole against fungi involved in dermal infections
In vitro-Aktivität von Fluconazol gegen Pilze als Erreger dermalen Infektionen
- 457–453 **A. Lukacs, H. C. Korting, A. Lindner.**
Case Reports. Successful treatment of griseofulvin-resistant tinea capitis in infants
Erfolgreiche Therapie griseofulvinresistenter Tinea capitis bei Kindern
- 455–459 **O. Binet, J. Soto-Melo, J. Delgadillo, S. Videla, I. Izquierdo, J. Forn, Flutrimazole Study Group.**
Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a randomized, multicentre, double-blind, comparative clinical trial with 1% clotrimazole cream
Flutrimazol-Creme (1%) zur Behandlung von Dermatomykosen: Eine randomisierte, multizentrische, gegen Clotrimazol-Creme (1%) im Vergleich durchgeführte Doppelblindstudie
- 461–467 **N. Noguchi, M. Hiruma, A. Kawada, A. Ishibashi.**
Tinea pedis survey in members of the Japanese Self-Defense Forces undergoing ranger training
Untersuchung zur Tinea pedis bei der japanischen Selbstverteidigungstruppe während der Truppenausbildung

Supplement 1

J. Müller, H. Bernhardt, M. Knoke.
Vorwort Preface

- 1–2 **J. Müller.**
MYK '93 Das Fenster hat sich geöffnet
- 2–3 Bilder von der MYK '93
- 4 **J. Müller.**
MYK '93 Brief des scheidenden Vorsitzenden an die Tagungsleiter
- 6–8 **J. Müller.**
MYK '93 Verleihung des Forschungsförderungspreises der Deutschsprachigen Mykologischen Gesellschaft
- 8 Ernennung zum Ehrenmitglied
- 10 Verleihung der Schönlein-Plakette 1993
- 11 **H. Ziegler-Böhme.**
Nachruf Horst Gemeinhardt 1928–1993
- 12 **J. Müller.**
Nachruf Wolfgang Loeffler 1923–1993
- 13–27 **O. Kandler.**
Festvortrag–Der Platz der Mikroorganismen im globalen phylogenetischen System der drei Domänen
The position of the microorganisms within the global phylogenetic system of the three domains
- 28–33 **M. Knoke, G. Schwesinger.**
Hundert Jahre Cryptococcose. Medizinische Mykologie im 19. Jahrhundert in Greifswald
One hundred years of cryptococcosis. Medical mycology in the 19th century in Greifswald
- 34–42 **J. Müller.**
Pathogenese, Immunbiologie und Epidemiologie der Cryptococcose
Pathogenesis, immunobiology and epidemiology of cryptococcosis
- 43–49 **B. R. Gedek.**
Gesundheitsgefährdung des Menschen durch Mykotoxine
Mycotoxins as health risks for man
- 50–56 **H. Bernhardt, K. Zimmermann, M. Knoke.**
Dimorphismus von *Candida albicans* im Modell der kontinuierlichen Kultur
Dimorphism of *Candida albicans* in the model of continuous flow culture
- 57–59 **B. Willinger, A. Berger, L. Li, A. M. Hirschl, Ch. Aspöck, A. Makristathis, P. M. Prückl, M. L. Rotter.**
Wechselfeld-Gelelektrophorese zur epidemiologischen Analyse von Sproßpilzisolaten
The Epidemiological Analysis of Yeasts by Pulsed Field Gel Electrophoresis
- 60–63 **M. Ruhnke, I. Tennagen, E. Engelmann.**
Korrelation zwischen Resistenztestung und Typisierung von *Candida albicans* – Isolaten bei AIDS-Patienten und chronisch rezidivierender oraler Candidose
Correlation between antifungal susceptibility testing and typing of *Candida albicans* isolates from patients with AIDS and chronic recurrent oropharyngeal candidosis
- 64–70 **S. Metzger, H. Jäger, H. Hofmann.**
Fluconazol-Empfindlichkeit von *Candida*-Arten in vitro im Mikrodilutionstest und Agardiffusionstest
In vitro susceptibility of *Candida* species to fluconazole by microdilution test and agar diffusion test
- 71–78 **E. Werle, R. Kappe, W. Fiehn, H.-G. Sonntag.**
Nachweis von Anti-*Candida*-Antikörpern der Klassen IgM, IgG und IgA mittels Enzymimmunoassays in sequentiellen Serumproben hospitalisierter Patienten
Detection of anti-*Candida* antibodies of IgM, IgG and IgA classes by enzyme immunoassays in sequential sera of hospitalized patients
- 79–83 **H. Freidank, Luzia Thiel, S. Henninger.**
Vergleich von Immundiffusion und Überwanderungs-Elektrophorese zum Nachweis präzipitierender Antikörper gegen *Candida*- und *Aspergillus*-Antigene
Comparison of immunodiffusion and counterimmunoelectrophoresis in demonstrating precipitation antibodies against *Candida* and *Aspergillus* antigens

- 84–88 **R. Blaschke-Hellmessen, R. Schwarze.**
Amphotericin B-Spiegel in Faeces und Serum während oraler Verabreichung bei Risikoneugeborenen
Amphotericin B concentration in faeces and serum during oral administration in new-borns at risk
- 89–96 **R. Blaschke-Hellmessen, I. Lauterbach, K.-D. Paul, K. Tintelnot, G. Weissbach.**
Nachweis von *Exophiala dermatitidis* (Kano) De Hoog 1977 bei Septikämie eines Kindes mit akuter lymphatischer Leukämie und bei Patienten mit Mukoviszidose
Isolation of *Exophiala dermatitidis* (Kano) De Hoog 1977 from a child with septicaemia in acute lymphatic leukaemia and from patients with cystic fibrosis
- 97–100 **H. Ulbright, K. Wörz.**
Therapie von Schimmelpilz-Onychomykosen mit Ciclopirox-Lack
Therapy of onychomycosis due to moulds with ciclopirox nail lacquer
- 101–104 **J. M. Pönnighaus, V. Gooskens, Yvonne Clayton, P. Mkandawire, J. Sterne.**
Zur Behandlung oberflächlicher Mykosen in den Tropen. Ergebnisse einer Doppelblindstudie im Karonga-Distrikt, Malawi
Treatment of superficial mycoses in the tropics. Results of a double-blind trial in Karonga District, Malawi
- 105–109 **A. Dunsche, A. Kerscher, H. Terheyden, H. Sahly.**
Indikation und Wirksamkeit von Fluconazol bei der oralen Candidose
Indication and efficacy of fluconazole in oral candidosis

Supplement 2

- J. Müller.**
Vorwort Preface
- 1–7 **J. Müller.**
Die Epidemiologie tieflokalisierter, einheimischer Mykosen
The epidemiology of deep-seated, domestic mycoses
- 8–19 **W. Fegeler.**
Aspekte zu Diagnostik tieflokalisierter, opportunistischer Mykosen
Aspects in diagnostics of deep-seated, opportunistic mycoses
- 20–26 **F. Martino.**
Die Behandlung der invasiven Aspergillose
Treatment of invasive aspergillosis
- 27–33 **G. Cauwenbergh.**
Pharmakokinetik von Itraconazol
Pharmacokinetics of itraconazole
- 34–39 **Dagmar Lampe, S. Kreutzberg, H.-J. Prümke.**
Therapeutisches Drug-Monitoring von Itraconazol–Ein Erfahrungsbericht
Therapeutic Drug Monitoring of itraconazole–A report of experiences
- 40–41 **V. Heinemann, U. Jehn.**
Vergleichende Untersuchung zur Pharmakokinetik verschiedener Amphoterein B-Präparationen
Comparative study on the pharmacokinetics of various amphoterein B-preparations
- 42–51 **W. Kreisel.**
Therapie invasiver Aspergillosen mit Itraconazol: Eigene Erfahrungen und Literaturübersicht
Therapy of invasive aspergillosis with itraconazole: own experiences and review of literature
- 52–55 **Fançoise Meunier.**
Die Therapie der invasiven Candidosen
Therapy of systemic candidoses
- 56–63 **Gudrun Just-Nübling.**
Die Therapie der Candidose und Cryptococcose bei AIDS
Therapy of candidosis und cryptococcosis in AIDS patients

- 64–69 **Theoni Petropoulou, J. Liese, Kathrin Tintelnot, M. Gahr, B. H. Belohradsky.**
Langzeitbehandlung mit Itraconazol zur Prophylaxe von *Aspergillus*-Infektionen bei Patienten mit chronischer Granulomatose (CGD)
Long-term treatment of patients with chronic granulomatous disease (CGD) for prophylaxis against *Aspergillus* infections
- 70–76 **M. Arning und C. Aul.**
Mykose-Prophylaxe bei neutroztopenischen Patienten
Prophylaxis against mycoses in granulocytopenic patients
- 77–82 **Françoise Meunier.**
Zukunftsperspektiven der antimykotischen Therapie
Future directions of antimycotic therapy
- 83 **J. Müller.**
Schlußwort und Zusammenfassung
- 84–88 **Anhang.**

SUBJECT INDEX

A

Absidia corymbifera 299
Achlya debaryana 61
 actinomycosis 209
 adherence 217
 adverse reaction 27 (S 2)
 aflatoxins 43 (S 1)
 Africa 249, 255
 agar diffusion test 64 (S 1)
 age variation 217
 agranulocytosis 181
 AIDS 209, 275, 367, 60 (S 1), 56 (S 2)
 allergic bronchopulmonary aspergillosis 171, 42 (S 2)
 allylamines 361
Alternaria alternata 181
 AmBisome 291, 275
 amphotericin B 17, 93, 123, 205, 275, 285, 291, 427, 433, 439, 84 (S 1), 40 (S 2), 70 (S 2)
 anaerobic growth 71, 349
 animal model 93, 109, 117, 191, 243
 antagonism 205
 anti-*Candida* antibodies 71 (S 1), 8 (S 2)
 antibody classes 199, 71 (S 1)
 antibody detection 71, 155, 313, 79 (S 1), 8 (S 2)
 antifungal activity 377
 antifungal spectrum 27 (S 2)
 antifungal susceptibility 357, 411
 antifungals 17, 27, 127, 411, 447, 455
 antigen detection 69, 117, 421, 8 (S 2)
 antimycotic chemotherapy 35, 39, 117, 123, 171, 275, 281, 361, 427, 433, 439, 443, 97 (S 1), 101 (S 1), 105 (S 1), 20 (S 2), 40 (S 2), 42 (S 2), 52 (S 2), 56 (S 2), 77 (S 2)
 antimycotic efficacy 27 (S 2)
 antimycotic prophylaxis 64 (S 2), 70 (S 2)
 army 461
 aspergilloma 171
 aspergillosis 117, 123, 209, 243, 329, 421, 433, 97 (S 1), 1 (S 2), 8 (S 2), 20 (S 2), 42 (S 2), 64 (S 2)
Aspergillus 79 (S 1)
Aspergillus arvi spec. nova 389
Aspergillus chevalieri 271
Aspergillus flavus 299
Aspergillus fumigatus 117, 123
Aspergillus niger 299
Aspergillus terreus 181
 azoles 35, 39, 117, 127, 131, 171, 243, 275, 281, 285, 357, 417, 433, 443, 447, 455, 457, 60 (S 1), 64 (S 1), 105 (S 1), 27 (S 2), 34 (S 2), 42 (S 2), 64 (S 2), 70 (S 2)

B

bait method 295
Basidiobolus 265
 bats 353
 bioassay 17, 84 (S 1)

mycoses **37** (1994)

biotransformation masking 43 (S 1)
 biotyping 401, 60 (S 1)
 black yeasts 235, 89 (S 1)
Blastomyces dermatitidis 149, 155
 blood culture 343
 boots 461
 bronchoalveolar lavage 329

C

caffeine 337
Candida 39, 101, 187, 199, 343, 353, 357, 64 (S 1), 79 (S 1), 84 (S 1), 52 (S 2)
Candida albicans 93, 191, 205, 285, 291, 299, 337, 349, 401, 50 (S 1), 57 (S 1), 60 (S 1)
Candida glabrata 285, 401, 57 (S 1)
Candida parapsilosis 285
Candida tropicalis 285
 candidosis 35, 131, 191, 199, 209, 243, 291, 329, 443, 105 (S 1), 1 (S 2), 8 (S 2), 52 (S 2), 56 (S 2)
 carry over 43 (S 1)
 cat fish 61
 cattle 389
 cerebral infection 123, 235, 275, 439, 34 (S 1), 20 (S 2), 42 (S 2), 56 (S 2)
 characterization 265
 chronic granulomatous disease 64 (S 2)
 ciclopirox 97 (S 1)
 clinical pictures 20 (S 2)
 clinical trials 455
 clotrimazole 357, 455, 101 (S 1)
 colorimetric assay 27
 combination therapy 56 (S 2)
 complement fixation test 313
Conidiobolus 265
 continuous flow culture 50 (S 1)
 contraindications 27 (S 2)
 counterimmunoelectrophoresis 79 (S 1)
 craniofacial infection 209
 cryptococcosis 23, 229, 275, 417, 439, 28 (S 1), 1 (S 2), 8 (S 2), 56 (S 2)
Cryptococcus neoformans 23, 69, 275, 325, 343, 411, 34 (S 1)
 cutaneous aspergillosis 271
 cutaneous candidosis 361
 cutaneous infection 3, 39, 43, 49, 137, 141, 249, 255, 271, 281, 361, 451, 455, 461, 101 (S 1)
 cyclophosphamide 93
 cystic fibrosis 235, 89 (S 1)
 cytokines 77 (S 2)
 cytology 337

D

deep-seated fungal infections 70 (S 2)
 deep-seated mycoses 1 (S 2)
 deferoxamine 427

delayed hypersensitivity 149
 dematiaceae 89 (S 1)
 denture stomatitis 131
 dermatomycosis 39, 455, 97 (S 1)
 dermatophytes 11, 39, 43, 49, 79, 85, 137, 141, 371, 377, 447, 97 (S 1), 101 (S 1)
 dermatophytosis 39, 43, 49, 137, 141, 451, 461, 101 (S 1)
 diagnostics 71, 8 (S 2)
 dialysis 161
 dimorphism 50 (S 1)
 dissemination 275, 433
 distribution pattern 27 (S 2)
 domain concept 13 (S 1)
 dosage 34 (S 2)
 drug concentrations 17, 127, 417, 84 (S 1), 27 (S 2), 34 (S 2)
 drug monitoring 34 (S 2)

E

ear 59
 ecology 53, 325
 ELISA 155
 econazole 357
 electronmicroscopy 317, 337, 377, 389, 393, 34 (S 1)
 enzymatic treatment 317
 enzyme characterization 85
 enzyme immunoassay 313, 71 (S 1)
 enzymes 11
 epidemiology 23, 43, 49, 187, 235, 325, 329, 34 (S 1), 1 (S 2)
Epidermophyton floccosum 79
 epizootic infection 61
Eurotium chevalieri 271
 evolution, 13 (S 1)
 exoenzymes 11
Exophiala dermatitidis 235, 89 (S 1)
 experimental infection 101

F

faeces levels 84 (S 1)
 females 249, 255
Filobasidiella bacillispora 34 (S 1)
Filobasidiella neoformans 34 (S 1)
 filtrate antigens 149
 fluconazole 35, 127, 205, 275, 281, 285, 417, 443, 447, 60 (S 1), 64 (S 1), 105 (S 1), 56 (S 2)
 flucytosine 123, 291, 275, 439
 flutrimazole 455
 fungaemia 187
 fungal reservoir 53, 59, 141, 325, 295, 34 (S 1), 1 (S 2)
 fungitoxicity 299
 fungus-specific primer system 79
Fusarium-mycosis 433

G

G-CSF 93, 70 (S 2)

Gabon 249, 255
 galactomannan 117
 gastrointestinal colonization 84 (S 1)
 genitopubic area 249
 genotyping 307
Geotrichum 3, 39, 101
 gliotoxin 43 (S 1)
 glucose tolerance factor (GTF) 405
 griseofulvin resistance 451
 growth inhibition 343

H

haemagglutination 71 (S 1)
 hepatosplenic candidosis 443
 histopathology 191
Histoplasma capsulatum 161, 313
 histoplasmosis 313
 history of medicine 28 (S 1)
 history of mycology 229
 history of science 229
 HIV infection 209, 275, 367, 64 (S 1), 56 (S 2)
 Hodgkin's disease 439
Hortaea werneckii 307
 host-fungus-relationship 34 (S 1)
 HPLC 17
 hydroxy-itraconazole 27
 hypersensitivity 149

I

identification 3
 IgG antibody 313
 immunobiology 34 (S 1)
 immunocompromised host 35, 123, 161, 171, 181, 187, 209, 275, 291, 329, 421, 427, 433, 439, 443, 84 (S 1), 89 (S 1), 20 (S 2), 56 (S 2), 64 (S 2), 70 (S 2), 77 (S 2)
 immunodiffusion test 79 (S 1)
 immunohistochemistry 117
 immunosuppression 191
 India 23
 infant 291, 451
 insulin 405
 intracranial abscess 123
 intensive care 187
 intertrigo 255
 Iran 43
 isoconazole 39
 itraconazole 27, 117, 171, 243, 285, 451, 27 (S 2), 34 (S 2), 42 (S 2), 56 (S 2), 64 (S 2)

K

keratinophilic fungi 295
 keratins 295
 ketoconazole 285, 337, 357, 361

L

Laboratory Branch CF 313
 lipid formulation 40 (S 2)
 liposomal formulation 40 (S 2)
 liver 389
 long-term therapy 34 (S 2)
 longitudinal study 71 (S 1)
 lysate antigens 149, 155

M

Malassezia furfur 39, 217, 367, 393
Malassezia pachydermatis 59
Mastacembelus armatus 61
 meningoencephalitis 439
 metabolism 43 (S 1)
 Mexico 49
 Mexico City 325
 miconazole 131, 357
 Microascaceae 71
 microdilution test 285, 64 (S 1)
 microimmunodiffusion 313
Microsporum canis 79, 141, 451
Microsporum cookei 377
Microsporum gypseum 79
 mode of action 27 (S 2)
 monospecific antisera 261
 morphogenesis 349
 morphological alterations 165
 moulds 97 (S 1)
 mouse 93, 191
 MTT assay 27
 mycoserology 117, 155, 199, 261, 291, 313, 401, 421, 34 (S 1), 57 (S 1), 71 (S 1), 79 (S 1), 8 (S 2), 42 (S 2)
 mycotoxicosis 43 (S 1)
 mycotoxins 43 (S 1)

N

nail lacquer 97 (S 1)
 neutropenia 93, 433
 new-borns 84 (S 1)
 Nigeria 39, 353
 nosocomial infection 187
 nutrients 11

O

obstructive uropathy 291
 ochratoxin A 43 (S 1)
 once-weekly treatment 281
 onychomycosis 97 (S 1)
 opportunistic fungi 71
 opportunistic mycoses 1 (S 2), 52 (S 2)
 oral candidosis 37 (S 1), 64 (S 1)
 oral infection 35, 209, 37 (S 1), 64 (S 1), 105 (S 1)

mycoses **37** (1994)

P

paediatrics 199
Paracoccidioides brasiliensis 165, 313
 pathogenesis 34 (S 1)
 pathogenetic determinants 11, 71
 PCR 79, 307
 pemphigus vulgaris 139
Penicillium nigricans 299
 peritonitis 161
 pharmacokinetics 127, 34 (S 2), 40 (S 2)
 photosensitivity 377
 phylogenetic system 13 (S 1)
 physiology 71
 pigeons 325
 pitted keratolysis 461
 pityriasis versicolor 39, 229, 28 (S 1)
 plasma levels 27 (S 2), 34 (S 2)
 ploidy 393
 polychemotherapy 421
 polymerase chain reaction 79, 307
 polymicrobial septicaemia 343
 pompholyx 137
 precipitating antibodies 79 (S 1)
 Premier™ EIA 313
 preservation 165
 prophylaxis 243, 84 (S 1), 70 (S 2)
 prostate 417
 proteases 85, 265
 protoplasts 317
Prototheca 101
Pseudallescheria boydii 69, 71
Pseudomonas aeruginosa 343
 pulsed field gel electrophoresis 401, 57 (S 1)
 pulmonary infection 171, 329, 421, 20 (S 2), 42 (S 2)
 purification 265

R

rat 109
 resistance 35, 451
Rhizopus 427
 risk factors 329, 20 (S 2), 42 (S 2), 52 (S 2)
 16S rRNA 13 (S 1)
 18S rRNA 79

S

Saccharomyces cerevisiae 405
Scedosporium prolificans 71
Scopulariopsis brevicaulis 11
 seborrhoeic dermatitis 217, 367
 second-hand car 141
 septicaemia 89 (S 1)
 serology 117, 155, 199, 261, 291, 313, 401, 421, 34 (S 1), 57 (S 1), 71 (S 1), 79 (S 1), 8 (S 2), 42 (S 2)
 serotyping 23, 60 (S 1)
 serum concentration 17, 84 (S 1)
 skin 127

skin infection 3, 39, 43, 49, 137, 141, 249, 255, 271, 281, 361, 451, 455, 461, 101 (S 1)
 skin test 149
 slide agglutination 261
 soil 295
 spiral hyphae 349
 sporotrichosis 281
 Sri Lanka 357
 stereotactic operation 123
 stomatitis 64 (S 1)
 stratum corneum cells 217
 structure 27 (S 2)
 surface/volume quotient 393
 susceptibility testing 3, 27, 271, 285, 60 (S 1), 64 (S 1)
 systemic infection 3
 systemic mycosis 109

T

taxonomy 71, 235
 tinea 39
 tinea capitis 451
 tinea nigra 307
 tinea pedis 461
 tissue response 191
 terbinafine 361
 therapy indication 42 (S 2)
 thiophenes 377
 topical therapy 97 (S 1)
 toxicity 27 (S 2)
 transmission 1 (S 2)
 triazole 243
 triazoles 70 (S 2)
Trichophyton mentagrophytes 79
Trichophyton rubrum 39, 79, 85, 137
Trichophyton terrestre 79
Trichophyton verrucosum 371
Trichosporon 3, 39, 249, 255, 261
Trichosporon asahii 255, 261, 3
Trichosporon beigelii 109, 3
Trichosporon inkin 255, 261, 3

Trichosporon mucoides 255, 261, 3
 trichothecenes 43 (S 1)
 tropical mycoses 101 (S 1)

U

ultrastructure 317, 337, 377, 393
 underlying diseases 52 (S 2)
 urease production 53

V

vaccine against ringworm 371
 vagina 191
 vaginal candidosis 357
 veterinary mycology 59, 61, 101, 353, 371, 389
 viability 165
 virulence 371
 volatile substances 299

W

Wangiella dermatitidis 235, 89 (S 1)
 water-closet 53
 white piedra 3, 249, 255
 Whitfield cream 101 (S 1)

Y

yeasts 187, 57 (S 1)

Z

zearalenones, 43 (S 1)
 zoo animals 59
 zoophilic dermatophytes 141
 zygomycosis 427

CASE REPORT

Fluconazole-resistant oral candidosis in a repeatedly treated female AIDS patient

Fluconazol-resistente orale Candidose bei einer wiederholt behandelten AIDS-Patientin

Eva Thoma-Greber¹, H. C. Korting¹, J. Bogner² and F.-D. Goebel²**Key words.** Candidosis, oral infection, antimycotic chemotherapy, fluconazole, resistance.**Schlüsselwörter.** Candidose, orale Infektion, antimykotische Chemotherapie, Fluconazol, Resistenz.

Summary. A 29-year-old female suffering from full-blown AIDS received fluconazole 400 mg day⁻¹ for a long period for treatment of oral candidosis, pseudomembranous type. She had previously received this drug repeatedly for the same reason, yet manifest disease persisted. She was therefore put on parenteral amphotericin B, which led to clinical, but not mycological, cure in the short term. IC₃₀ testing revealed a minimum inhibitory concentration (MIC) > 128 µg ml⁻¹ for fluconazole. The isolate, however, was susceptible *in vitro* to ketoconazole, itraconazole and amphotericin B. The same antimicrobial susceptibility pattern was found with a second isolate obtained later. Resistance to fluconazole might become a major problem in HIV-infected patients receiving this drug for long periods.

Zusammenfassung. Eine 29-jährige manifest an AIDS erkrankte Patientin erhielt 400 mg Fluconazol per os über längere Zeit zur Behandlung einer oralen Candidose vom pseudomembranösen Typ. Eine daraufhin erfolgte Umstellung der Therapie auf Amphotericin B parenteral führte zur klinischen, nicht aber zur mykologischen Heilung in der kurzen Frist. Die IC₃₀-Testung des *Candida albicans*-Isolates erbrachte eine minimale Hemm-

konzentration (MHK) für Fluconazol von > 128 µg ml⁻¹. Das Isolat war demgegenüber *in vitro* empfindlich gegenüber Ketoconazol, Itraconazol und Amphotericin B. Korrespondierende Empfindlichkeit wies auch ein konsekutives Isolat aus. Fluconazol-Resistenz könnte ein größeres Problem bei HIV-infizierten Patienten werden, die dieses Medikament über längere Zeit erhalten.

Introduction

Oral candidosis is considered to be one of the earliest signs of HIV infection. It develops in one-third to one-half of HIV-seropositive persons according to a recent in-depth review [1]. The frequency of oral candidosis seems to be linked to the stage of HIV infection and to the T4/T8 ratio [2]. It has been speculated that candidosis may adversely influence the prognosis of the patient because of the immunosuppressive effect of *Candida* species [3]. Early treatment of oral candidosis in HIV-infected patients is also considered mandatory to prevent spread of fungal disease [4].

Nowadays a variety of antimycotics are available for the treatment of oral candidosis in HIV-infected patients [5]. For initial therapy ketoconazole, itraconazole and fluconazole are particularly recommended. In this context the daily dose of antimycotic is least with fluconazole, amounting to 50 mg [5]. In fact, in a comparative clinical trial fluconazole proved to be slightly superior to ketoconazole [6]. More recently, fluconazole 100 mg day⁻¹ has also been proven to be superior

¹Department of Dermatology and ²Department of Internal Medicine, Ludwigs-Maximilians-University, Munich, Germany.

Correspondence: Prof. Dr Hans C. Korting, Dermatologische Klinik der Universität, Frauenlobstr. 9, D-80337, München, Germany.

to ketoconazole 200 mg day⁻¹ in *Candida* oesophagitis in AIDS patients [7]. Yet higher efficacy *in vivo* is not linked to higher activity *in vitro*. Minimum inhibitory concentrations using a macro-broth dilution assay revealed fluconazole to be about 16-fold less active than ketoconazole against 35 *Candida albicans* isolates [8].

Although fluconazole seems to be efficacious in most patients suffering from oral candidosis associated with HIV infection, this cannot be expected in every patient. In recent years clinical failure with fluconazole has repeatedly been traced back to inadequate *in vitro* activity as expressed by high minimum inhibitory concentrations (MICs) [9–13]. In the following we report on a further case recently observed.

Case report

History

A 29-year-old female had undergone blood transfusion for hypermenorrhoea-associated anaemia at the age of 21 years. Three years later, in 1987, she suffered from weight loss, relapsing fever and nocturnal sweating. In 1988 the patient for the first time attended the Department of Internal Medicine, and AIDS-related complex was diagnosed on both clinical and serological grounds. At that time oral candidosis was manifest, the patient was anergic in the Meri  ux test and the CD4 count was 56 µl⁻¹. For 1 year, the patient was put on zidovudine. Owing to relapsing oral candidosis the patient was repeatedly treated with topical amphotericin B, oral ketoconazole and fluconazole. Moreover, the patient was once treated with amphotericin B parenterally. This was because of elevated liver enzymes in the blood linked to the application of fluconazole. In July 1990 *Candida* oesophagitis was successfully treated with oral ketoconazole.

In August 1989 the patient suffered from persistent herpes simplex of the disseminated type. Thus the diagnosis of full-blown AIDS was established. In April 1991 atypical mycobacteriosis of the disseminated type due to *Mycobacterium kansasii* infection was found.

From February 1992 onwards the patient suffered from persistent oral candidosis refractory to various treatment protocols including fluconazole 400 mg day⁻¹ orally and also fluconazole parenterally.

Clinical findings

When the patient was referred to the outpatient department of the Department of Dermatology,




Figure 1. Oral candidosis in a patient suffering from full-blown AIDS. Whitish plaques surrounded by marked erythema at the tongue and the palate.

inspection of the oral cavity revealed whitish plaques surrounded by marked erythema mainly on the tongue and the hard and soft palate but to a certain extent also in the buccal region (see Fig. 1). The diagnosis of oral candidosis of the pseudo-membranous type was established on clinical and mycological grounds.

Treatment and course of disease

In the Department of Internal Medicine the patient was put on parenteral amphotericin B. This led to clinical cure in the short term. After relapsing the patient was again referred to the Department of Dermatology and material was obtained for identifying the causative organism and characterizing its antimicrobial susceptibility. The analysis was repeated 4 weeks later.

Laboratory findings

In both cases a yeast was grown using standard cultural techniques. The species *Candida albicans* was identified by germ tube assay. Antimicrobial susceptibility to various antimycotics was determined using the IC₃₀ test as described by Johnson *et al.* [13]. The MIC values of ketoconazole, itraconazole, fluconazole and amphotericin B are shown in Table 1.

Discussion

The *in vitro* susceptibility of *Candida albicans* isolates from HIV-infected patients has been demonstrated to differ according to the stage of HIV infection of the host in that inhibitory concentrations are higher with isolates from patients with manifest AIDS [2]. Recently, an association between reduced susceptibility to ketoconazole and high

Table 1. Antimicrobial susceptibility of *Candida albicans* strains ($\mu\text{g ml}^{-1}$) according to the IC_{30} test

Strain*	Ketoconazole	Itraconazole	Fluconazole	Amphotericin B
1	0.25	0.25	> 128	2
2	4	8	> 128	2

*Consecutive isolates.

activity of a protease characteristic of strains isolated from HIV-infected patients was demonstrated [14]. Moreover, in a clinical trial a change from susceptibility to resistance against ketoconazole, which was also clinically relevant, could be demonstrated [15]. In this case, the definitory requirement for development of azole resistance by *Candida albicans* as postulated by Warnock [16] was fulfilled. However, Fan-Havard *et al.* [17] were not able to detect a generally higher resistance of *Candida* isolates from HIV-infected patients with oral candidosis. Yet in an individual case *in vitro* resistance to ketoconazole, fluconazole and amphotericin B was linked to corresponding *in vivo* resistance. In the cases of fluconazole resistance of *Candida albicans* from the oral cavity of HIV-infected patients, fluconazole resistance was either isolated [9–11] or paralleled by a lack of susceptibility to ketoconazole [9]. Currently, the relevance of such an *in vitro* finding is the subject of debate. In particular, it has been questioned if the difference in the MICs between fluconazole and other azoles such as ketoconazole is a true one or results from current not entirely adequate testing procedures [16].

Yet it must be remembered that the question of azole resistance of *Candida albicans* strains from patients with both HIV infection and oral candidosis was raised at the time when fluconazole was introduced into the treatment of this entity on a large scale. In addition, it cannot be overlooked that prophylactic treatment has particularly been suggested since fluconazole became available, and in fact a remarkable number of the cases of fluconazole resistance that have been reported have occurred in this context [10, 12]. Taking a relatively low *in vitro* activity of fluconazole for granted, it is tempting to speculate that in particular low-dose oral fluconazole might in future cause a problem of more widespread resistance. And one cannot currently exclude the possibility that decreased activity of fluconazole might also be paralleled by reduced activity of other azoles such as ketoconazole. This appears to be even more relevant as the mechanism of resistance of all azoles is considered to be the same [16].

The experience of fluconazole resistance *in vitro* in individual patients not responding to corre-

sponding therapy clinically implies that antimicrobial susceptibility testing using adequate methods should be implemented in more clinical centres in future. Although the ideal method has certainly not yet been identified [16, 18], the method to be used in general should be defined in an international consensus conference. From our own experience we would suggest a microdilution test with objective reading and comparison with a control such as the IC_{30} test [19].

References

- 1 Samaranayake, L. P. (1992) Oral mycoses in HIV infection. *Oral Surg. Oral Med. Oral Pathol.* **73**, 171–180.
- 2 Korting, H. C., Ollert, M., Georgii, A. & Fröschl, M. (1988) In vitro susceptibilities and biotypes of *Candida albicans* isolates from the oral cavities of patients infected with human immunodeficiency virus. *J. Clin. Microbiol.* **26**, 2626–2631.
- 3 McCarthy, G. M. (1992) Host factors associated with HIV-related oral candidiasis. *Oral Surg. Oral Med. Oral Pathol.* **73**, 181–186.
- 4 Anonymous (1989) Oral candidosis in HIV infection. *Lancet* **ii**, 1491–1492.
- 5 British Society for Antimicrobial Chemotherapy Working Party (1992) Antifungal chemotherapy in patients with acquired immunodeficiency syndrome. *Lancet* **ii**, 648–651.
- 6 De Wit, S., Weerts, D., Goossens, H. & Clumeck, N. (1989) Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. *Lancet* **i**, 746–748.
- 7 Laine, L., Dretler, R. H., Contreas, C. N., Tuazon, C., Koster, F. M., Sattler, F., Squires, K. & Islam, M. Z. (1992) Fluconazole compared with ketoconazole for the treatment of *Candida* esophagitis in AIDS. *Ann. Intern. Med.* **117**, 655–660.
- 8 Rogers, T. & Galgiani, J. N. (1986) Activity of fluconazole (UK 49,858) and ketoconazole against *Candida albicans* *in vitro* and *in vivo*. *Antimicrob. Agents Chemother.* **30**, 418–422.
- 9 Fox, R., Neal, K. R., Leen, C. L. S., Ellis, M. E. & Mandel, B. K. (1991) Fluconazole resistant *Candida* in AIDS. *J. Infect.* **22**, 201–204.
- 10 Kitchen, V. S., Savage, M. & Harris, J. R. W. (1991) *Candida albicans* resistance in AIDS. *J. Infect.* **22**, 204–205.
- 11 Smith, D., Boag, F., Midgley, J. & Gazzard, B. (1991) Fluconazole resistant *Candida* in AIDS. *J. Infect.* **23**, 345–346.
- 12 Willocks, L., Leen, C. L. S., Brettell, R. P., Urquhart, D., Russell, T. B. & Milne, L. J. R. (1991) Fluconazole resistance in AIDS patients. *J. Antimicrob. Chemother.* **28**, 937–939.
- 13 Johnson, E. M., Richardson, M. D. & Warnock, D. W. (1984) *In vitro* resistance to imidazole antifungals in *Candida albicans*. *J. Antimicrob. Chemother.* **13**, 547–558.
- 14 Ollert, M., Korting, H. C., Grebel, C., Görlich, M.,

- McMullen-Vogel, C. & Vogel, C. W. (1994) Evidence for increased expression of the secretory virulence enzyme aspartyl protease in *C. albicans* isolates from HIV-infected patients. *J. Infect. Dis.* (submitted for publication).
- 15 Korting, H. C., Blecher, P., Fröschl, M. & Braun-Falco, O. (1992) Quantitative assessment of the efficacy of oral ketoconazole for oral candidosis in HIV-infected patients. *Mycoses* **35**, 173–176.
- 16 Warnock, D. W. (1992) Azole drug resistance in *Candida* species. *J. Med. Microbiol.* **37**, 225–226.
- 17 Fan-Havard, P., Capano, D., Smith, S. M., Mangia, A. & Eng, R. H. K. (1991) Development of resistance in *Candida* isolates from patients receiving prolonged antifungal therapy. *Antimicrob. Agents Chemother.* **35**, 2302–2305.
- 18 Galgiani, J. N. (1987) Antifungal susceptibility tests. *Antimicrob. Agents Chemother.* **31**, 1867–1870.
- 19 Korting, H. C. & Georgii, A. (1988) Antimykotikatestung dermatovenerologisch bedeutsamer Hefen: Methoden, Ergebnisse und klinische Relevanz. *Hautarzt* **39**, 343–347.